|Slideshows|December 31, 2022

The Year in Special Reports

Revisiting the Special Reports featured in Psychiatric Times throughout 2022.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Premature Mortality in Schizophrenia: What Clinicians Can Do

ByFaith Dickerson, PhD, MPH

May 18th 2026

Examining Ethnoracial Disparities in the Prevalence of Schizophrenia Spectrum Disorders

ByLeah Kuntz,Mark Olfson, MD, MPH

May 15th 2026

Understanding Schizophrenia as We Enter an AI Era: The Clinician Knows Best?

ByPeter F. Buckley, MD

May 14th 2026

Sex Hormones and Eating Disorders: An Evolving Relationship

ByLeah Kuntz,Tom Hildebrandt, PsyD

April 23rd 2026

Prolactin Monitoring for Antipsychotics and the Impact of Stress

ByNilamadhab Kar, MD, DPM, DNB, FRCPsych

April 22nd 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

The Year in Special Reports

Related Content

Premature Mortality in Schizophrenia: What Clinicians Can Do

Examining Ethnoracial Disparities in the Prevalence of Schizophrenia Spectrum Disorders

Understanding Schizophrenia as We Enter an AI Era: The Clinician Knows Best?

Sex Hormones and Eating Disorders: An Evolving Relationship

Prolactin Monitoring for Antipsychotics and the Impact of Stress

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FDA Issues CRL for CTx-1301 for Treatment of ADHD

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability

New Name, New Path for Psychiatry: The Future of the DSM

Endangered Education: Psychiatric Professional Degrees Under Attack